Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 known ✓ | P36507 | 1/20 | 0.62 |
| ▸ | MAP2K1 known ✓ | Q02750 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 17/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.62 |
| ▸ | KIT | P10721 | 2/20 | 0.62 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.62 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | STK17B | O94768 | 1/20 | 0.62 |
| ▸ | STK10 | O94804 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18138468 | 0.99 | EGFR (0.68) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL18138482 | 0.97 | EGFR (0.66) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL16809094 | 0.97 | EGFR (0.71) | EGFRERBB2SRCKITERBB3 | |
| Bromide SCHEMBL18138475 | 0.97 | EGFR (0.70) | EGFRERBB2SRCKITERBB3 | |
| Hydrochloric Acid SCHEMBL18138465 | 0.97 | EGFR (0.70) | EGFRERBB2SRCKITERBB3 | |
| Phosphoric Acid SCHEMBL18138470 | 0.95 | EGFR (0.69) | EGFRERBB2SRCKITERBB3 | |
| Acetic Acid SCHEMBL20496158 | 0.95 | EGFR (0.69) | EGFRERBB2SRCKITERBB3 | |
| Oxalic Acid SCHEMBL20496149 | 0.95 | EGFR (0.69) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL18138479 | 0.95 | EGFR (0.63) | EGFRERBB2SRCKITERBB3 | |
| SCHEMBL18138477 | 0.94 | EGFR (0.63) | EGFRERBB2SRCKITERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081563-B1 | QUINAZOLINE DERIVATIVE AND SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | claimed |
| US-9840494-B2 | Quinazoline derivative | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-12-12 | — | — | US | claimed |
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD | 2016-10-27 | — | — | US | claimed |
| EP-3081563-A1 | QUINAZOLINE DERIVATIVE | Tianjin Hemay Pharmaceutical Sci-tech Co. Ltd. (CN) | 2016-10-19 | — | — | EP | claimed |
| EP-3081563-B1 | QUINAZOLINE DERIVATIVE AND SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-9840494-B2 | Quinazoline derivative | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD | 2016-10-27 | — | — | US | disclosed |
| EP-3081563-A1 | QUINAZOLINE DERIVATIVE | Tianjin Hemay Pharmaceutical Sci-tech Co. Ltd. (CN) | 2016-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | NQO2, ABL1, HDAC6 | MAP2K2 1987/4885MAP2K1 2698/4885EGFR 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.